Hello MSOS Members - Would you mind sharing what are your metrics for NPSG AC management, benchmark use and opportunities for improvement at your institutions.

Thank you in advance for your help!

Hello,

We typically stock meperidine 25 mg/mL single dose vials/carpujects (currently on ASHP shortage list), however we were able to purchase an alternative concentration to have the medication available temporarily. Has anyone been able to implement an effective way to emphasize a different concentration is being stocked compared to our usual product?

Per ASHP drug shortage information, the listed available meperidine product is a 50 mg/mL, 30 mL multiple dose vial. Does anyone have plans to use this product, and if yes what safeguards are you planning to implement?

We are starting the process of looking at our high-alert medication list since our last update a few years ago. I would appreciate any information (list or policy) that other pediatric institutions have and any strategies your institution uses if a double check process is not required around a high alert medication. Thanks!

Hi - does anyone's team routinely check mannitol vials in their ADC cabinets to see if there is crystallization?

Our organization is administering twice daily nasal decolonization with mupirocin for our adult patients admitted to a critical care unit. An order is built into our ICU admission and transfer orders to start 5 days of therapy.

If you are doing this, which presentation are you using (i.e., ointment vs cream).

Hello all,

Given the recent ISMP recommendation to align with ASPEN guidelines recommending a maximum hang-time of 12 hours for ILE, how has your organization handled the Epic/logistical dispensing aspect of switching lipids out at 12 hours? Any successes and/or pain points would be helpful!

Thanks,

Rachel

Looking to see if any sites are actively adding outpatient oncology treatment plans to patient's home med lists when completing admission medication reconciliation.

We utilize EPIC, and within our health network you can see if the patient is on an active therapy / treatment plan via the storyboard. Looking more specifically at patients that may receive oncology care outside of our health network and the best place to document when they last received their treatment, what the treatment is, etc.

Hello,

I am hoping to get insight on your experience with barcode scanning at omnicell dispense.

1. Has your institution activated bcma at adc dispense? (Ours is a meditech/omnicell system, soon to transition to epic)

2. if yes, do you have it turned on for specific meds only or all meds?

3. do you have a defined policy for this?

4. how did you go about operationalizing this? how did you decide which meds or drug classes to include?

I appreciate your help and input.

Greetings,

We are evaluating remifentanil for addition to formulary for OR cases where EEG monitoring would be used. Fentanyl and sufentanil are already on formulary and we do not have BCMA in procedural spaces.

For those with remifentanil in the OR, what safety strategies are you using?

Thanks,
Starr-Mar'ee Bedy